arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TriSalus Life Sciences, Inc.

TLSI
$3.53 ▼ -0.37 (-9.49%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
24 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
54
Health
Fair
Neutral
auto_awesome

Analytical Summary

TriSalus Life Sciences, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $205.8M
Dividend Yield —
Revenue Growth 1.7% ↗
Op. Margin -86.0% ↗
ROIC -24.8% ↘
FCF / Share $-0.18 ↘
Trailing P/E —
Price / Book 33.1x
FCF Yield —
Debt / Equity 5.05
info Valuation on last close. End-of-day price, Nov 5, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.41M
↑ +1.7% —
Net Income Profit after all expenses
$1.54M
— 0.0% —
Operating Margin Operating profit as % of sales
-86.0%
↑ +9.0% 4th
FCF / Share Free cash flow per share
$-0.18
↓ -36.3% —
Long-Term Debt Long-term obligations
$33.06M
— 0.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
4
Returns
99
Financial Health ↑
67
Cash Quality
39

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 24 quarters